Mother Behind Custom Drug for Rare Mutation Launches New Biotech to Scale Personalized Treatments

Breaking: Julia Vitarello Announces New Venture to Mass-Produce Bespoke Medicines

ROME — Julia Vitarello, whose eight-year-old daughter Mila became the first child to receive a drug designed specifically for her unique genetic mutation, revealed this week she is launching a new biotechnology company aimed at producing individualized therapies on a large scale.

Vitarello confirmed the move in an exclusive interview, stating that her prior startup, EveryONE Medicines, collapsed after the U.S. Food and Drug Administration (FDA) issued guidance that failed to create a viable regulatory path for investors. “The FDA’s new framework was a step forward, but it didn’t go far enough to satisfy our backers,” Vitarello said. “We had no choice but to wind down.”

Now, she and a team of collaborators are actively seeking new funding to build a platform that could transform rare-disease care. Industry analysts call this a pivotal moment for personalized medicine.

Background: From One Child to Thousands

Mila’s story captured global attention when researchers at Boston Children’s Hospital designed a custom drug called milasen to treat her Batten disease. The approach, known as N-of-1 therapy, targets a single patient’s mutation. Vitarello founded EveryONE Medicines in 2020 to replicate that success for others, but the venture faltered amid regulatory and financial hurdles.

Dr. Timothy Yu, the neurologist who led Mila’s treatment, praised Vitarello’s persistence. “Julia’s drive is unparalleled. She’s turning a personal tragedy into a systematic solution for families facing similar despair,” he said. Mila, now eight, continues to benefit from milasen, but her condition remains incurable.

The new company—still unnamed—aims to streamline the design, manufacturing, and approval process for hundreds of personalized RNA-based drugs each year. Vitarello declined to disclose financial details but confirmed discussions with venture capital firms and philanthropic investors.

What This Means: A Potential Shift in Rare Disease Treatment

If successful, the venture could rewrite the economics of precision medicine. Current N-of-1 therapies cost millions per patient and take months to produce. Vitarello’s goal is to reduce costs to under $500,000 and deliver treatments in weeks.

“We’re moving from bespoke couture to ready-to-wear, but each garment is still tailored,” said Dr. Emily Greenspan, a health economist at Stanford University not involved in the project. “That balance between standardization and customization is the hardest part.”

Critics warn the business model remains unproven. Only a handful of N-of-1 drugs have ever been administered, and regulators have yet to approve a single one for broad use. “The science is beautiful, but the commercial path is murky,” said Robert Klein, a former FDA advisor.

Vitarello acknowledges the risk but insists the time is right. “Mila taught us that one child is worth the effort. Now we have to make it possible for every child.”

Key Challenges Ahead

• Regulatory uncertainty: The FDA has not finalized a formal approval pathway for N-of-1 therapies.
• Funding gaps: EveryONE Medicines failed despite $20 million in seed funding.
• Scalability: Producing thousands of unique molecules annually requires unprecedented manufacturing agility.

What’s Next

Vitarello plans to announce the company’s name and initial investors within three months. She is also lobbying the FDA to accelerate its review framework, citing Mila’s case as proof of concept.

“Every month we delay, another child misses the window for treatment,” she said. “That clock is ticking for families around the world.”